1. FDA Approves Eli Lilly's Foundayo Obesity Pill, Igniting Direct Rivalry with Novo Nordisk's Wegovy
The FDA has greenlit Eli Lilly's oral obesity drug, Foundayo (orforglipron), directly challenging Novo Nordisk's dominance in the lucrative GLP-1 market. This approval, granted under a special fast-track program for national health priorities, signals a pivotal shift as the pharmaceutical giants prepare for a head-to-h...